Akums Drugs & Pharmaceuticals Limited has received a reaffirmed credit rating of [ICRA]AA (Stable)/A1+ for its working capital facilities. Additionally, the company has been assigned an [ICRA]A1+ rating for its proposed Rs. 200 crore commercial paper programme. These ratings reflect the company’s strong market position as a leading contract manufacturer, healthy financial profile, and stable outlook, supported by its significant manufacturing capacities and robust liquidity position.
Strengthened Financial and Market Position
Akums Drugs & Pharmaceuticals Limited (ADPL) continues to demonstrate financial resilience as a leading contract manufacturer in the domestic generic formulations industry. The company, which maintains a combined production capacity of approximately 49.6 billion units per annum across 14 manufacturing units, has seen its credit standing reaffirmed by ICRA. The stable outlook is driven by the company’s strong performance in its CDMO business, which generated Rs. 2,533 crore in revenue during 9M FY2026, marking a 7% year-on-year growth.
Strategic Growth and Liquidity
The company’s liquidity position remains strong, reinforced by an upfront payment of EUR 100 million received in Q1 FY2026 related to a long-term European contract. As of September 30, 2025, ADPL reported cash and cash equivalents of Rs. 1,654.4 crore against a total debt of only Rs. 90.3 crore. This conservative debt profile results in a healthy total debt/OPBDITA ratio of 0.2 times, providing significant headroom for future operations.
Future Expansion and Outlook
Looking ahead, ADPL is focusing on geographical diversification. While domestic operations have historically accounted for the vast majority of revenues, the company is preparing for growth in international markets, including Europe and Zambia, with sales expected to commence over CY2027. To support this growth, the company plans an annual capital expenditure of approximately Rs. 250 crore through FY2028, aimed at building new facilities and maintaining current infrastructure. This expansion is expected to be funded through internal accruals and existing liquidity.
Source: BSE
